Please assess the completion status of the following clinical trial:

Trial Title: Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 antibody positive~* On a virologically suppressive regimen for at least 24 weeks and stable on a PI/r (ATV, LPV or DRV) plus Truvada or Kivexa for at least 4 weeks prior to screening~* Current HIV-1 RNA \<50cps/ml plasma on 2 occasions \>4 weeks apart~* No prior CCR5 or CXCR4 antagonist use~* Prior tetanus toxoid immunisation or known tetanus antibodies. Immunisation must have taken place in the past 10 years, but not within 1 month of baseline visit.~* Known CD4 nadir~* If the subject is a woman of child bearing potential, she must agree to use a double barrier method of contraception~* Willing and able to provide written informed consent~* At least 18 years old~Exclusion Criteria:~* Current or prior immunologically active agents (use of IL-2, GH or GHRH, corticosteroids (except inhaled), G- and GM-CSF) deemed to potentially impact study results.~* History of HIV, cholera or meningococcal immunisation~* Other known immune deficiency or use of immune suppressant~* History of malignancy (except low volume Kaposi's sarcoma) or chemotherapy~* Contraindication to maraviroc~* Peanut or soya allergy~* Antiretroviral agents other than those in inclusion list~* Drugs known to reduce exposure to maraviroc (CYP3A inducers)~* Contraindication to vaccines or vaccine components and/or components of skin test kits~* Pregnant or lactating or planning to become pregnant during the study period~* Acute feverish, stomach or intestinal illness~* Received an investigational medicinal product as part of a clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Nadir CD4 count \>200 cells/µl blood and randomised to Maraviroc 150mg BD
- Group 2 (Type: PLACEBO_COMPARATOR): Nadir CD4 count \>200 cells/µl blood and randomised to placebo twice daily for 24 weeks
- Group 3 (Type: ACTIVE_COMPARATOR): Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
- Group 4 (Type: PLACEBO_COMPARATOR): Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).